Blar i NTNU Open på forfatter "Jacobsen, Kari Dolven"

Viser treff 1-3 av 3

    • 2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data 

      Ottesen, Jon André; Yi, Darvin; Tong, Elizabeth; Iv, Michael; Latysheva, Anna; Saxhaug, Cathrine; Jacobsen, Kari Dolven; Helland, Åslaug; Emblem, Kyrre E; Rubin, Daniel L.; Bjørnerud, Atle; Zaharchuk, Greg; Grøvik, Endre (Peer reviewed; Journal article, 2023)
      Introduction: Management of patients with brain metastases is often based on manual lesion detection and segmentation by an expert reader. This is a time- and labor-intensive process, and to that end, this work proposes ...

    • Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment 

      Aamdal, Elin; Skovlund, Eva; Jacobsen, Kari Dolven; Straume, Oddbjørn; Kersten, Christian; Herlofsen, Oluf; Karlsen, Jarle; Hussain, Israr; Amundsen, Anita; Dalhaug, Astrid; Nyakas, Marta Sølvi; Hagene, Kirsten Thorin; Holmsen, Kjersti; Aamdal, Steinar; Kaasa, Stein; Guren, Tormod Kyrre; Kyte, Jon A (Peer reviewed; Journal article, 2022)
      Background We have previously reported that the safety and efficacy of ipilimumab in real-world patients with metastatic melanoma were comparable to clinical trials. Few studies have explored health-related quality of ...

    • Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up 

      Aamdal, Elin; Jacobsen, Kari Dolven; Straume, Oddbjørn; Kersten, Christian; Herlofsen, Oluf; Karlsen, Jarle; Hussain, Israr; Amundsen, Anita; Dalhaug, Astrid; Nyakas, Marta Sølvi; Schuster, Cornelia; Hagene, Kirsten Thorin; Holmsen, Kjersti; Russnes, Hege Elisabeth Giercksky; Skovlund, Eva; Kaasa, Stein; Aamdal, Steinar; Kyte, Jon A.; Guren, Tormod Kyrre (Peer reviewed; Journal article, 2021)
      Ipilimumab was the first treatment that improved survival in advanced melanoma. Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and less intensive ...